Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Adaptimmune Therapeutics

04/11/2021 13:32

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 26 cents per share.
* Revenue rose 0.8% to $1.20 million from a year ago;  analysts
expected $1.37 million. 
* Adaptimmune Therapeutics PLC's reported EPS for the quarter
was a loss of 30 cents​.
* The mean earnings estimate of analysts had fallen by
about 5.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Adaptimmune Therapeutics PLC shares had risen by 5.8% this
quarter and gained 1.5% so far this year.
* The company reported a quarterly loss of $42.4 million.
* Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $8.00 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 
This summary was machine generated November 4 at 01:31 p.m.
 ​All figures in US dollars unless otherwise stated